Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6105207 | 0.83 | KMT2A (0.43) | MAPK14POLBALDH1A1KMT2APTGS1 | |
| SCHEMBL6107595 | 0.78 | CFTR (0.41) | MAPK14POLBPTGS2ALDH1A1KMT2A | |
| SCHEMBL6108102 | 0.78 | MAPK14 (0.36) | MAPK14POLBLMNA | |
| SCHEMBL5457630 | 0.78 | MAPK14 (0.63) | MAPK14POLBPTGS2ALDH1A1KMT2A | |
| SCHEMBL9753114 | 0.78 | MAPK14 (0.42) | MAPK14POLBPTGS2ALDH1A1KMT2A | |
| SCHEMBL5208134 | 0.77 | MEN1 (0.42) | MAPK14POLBALDH1A1KMT2ALMNA | |
| SCHEMBL6106910 | 0.76 | HSD17B10 (0.42) | MAPK14ALDH1A1KMT2ALMNAADORA3 | |
| SCHEMBL5208807 | 0.75 | MAPK14 (0.36) | MAPK14POLBPTGS2ALDH1A1KMT2A | |
| SCHEMBL5457469 | 0.74 | MAPK14 (1.00) | MAPK14PTGS2ADORA3ADORA1ADORA2A | |
| SCHEMBL29208147 | 0.73 | MEN1 (0.38) | MAPK14ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2256/4885POLB 3250/4885PTGS2 703/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885POLB 1714/4885PTGS2 1151/4885 |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | MAPK14 2533/4885POLB 3778/4885PTGS2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.